Immune checkpoints proteins, such as Programmed cell Death 1 (PD1), PD1 ligand (PD-L1)
and Cytotoxic T-lymphocyte Associated Protein-4 (CTLA4) are expressed by effector
immune cells, antigen-presenting cells or malignant cells and promote immunotolerance
towards tumors. Immune checkpoint inhibitors (ICI), such as the anti-PD1 monoclonal
antibody Nivolumab, enhance the immune response against malignant cells and have proven
to be efficient as first or second-line therapy for various types of malignancies.
As the use of ICI expands, specific immune-related adverse effects (irAE) involving
various organs have been reported and are considered to be caused by immune over activation.
IRAE involving the nervous system or muscle are rare and remain poorly described.
We hereby report a case of biopsy-proven myositis in a patient treated with Nivolumab
and provide a review of the literature.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Fulminant myocarditis with combination immune checkpoint blockade.N. Engl. J. Med. 2016 Nov 3; 375: 1749-1755
- New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.Melanoma Res. 2017 Apr; 27: 155-158
- Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine.Leuk. Lymphoma. 2017 Aug; 58: 2011-2013
- Case of respiratory discomfort due to myositis after administration of nivolumab.J. Dermatol. 2015 Oct; 42: 1008-1009
- Myasthenic crisis and polymyositis induced by one dose of nivolumab.Cancer Sci. 2016 Jul; 107: 1055-1058
- A case of Nivolumab-induced myositis.Oncologist. 2016 Dec; 21e3
- Continued response to one dose of Nivolumab complicated by Myasthenic crisis and myositis.J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer. 2017 Jul; 12: e90-1
- Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.J. Immunother. Cancer. 2016; 4: 36
- Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.Neurology. 2017 Aug 18; 89: 1127-1134
- Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report.Medicine. 2017 Jul; 96e7350
- Effets secondaires inhabituels des immunothérapies dans le cancer bronchique non à petites cellules: à propos de deux cas.Rev. Pneumol. Clin. 2017; 73 (Nov [cited 2017 Dec 3. (Available from:)): 326-330
- Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities.J. Crohns Colitis. 2017; 11 ([Internet]. [cited Sep 4e]. (Available from:)): 1238-1246
- Neurological toxicities associated with immune-checkpoint inhibitors.Curr. Opin. Neurol. 2017 Dec; 30: 659-668
Article info
Publication history
Published online: February 05, 2018
Accepted:
January 24,
2018
Received in revised form:
January 9,
2018
Received:
December 10,
2017
Identification
Copyright
© 2018 Elsevier B.V. All rights reserved.
